<DOC>
	<DOCNO>NCT01382511</DOCNO>
	<brief_summary>Simvastatin related statin , compactin , able inhibit constitutive expression inducible/repressible keratin gene K6a K17 . This effect due report ability statin inhibit STAT1 expression ( Lee et al. , 2007 ) . The constitutive K6a promoter activity dependent STAT1 block simvastatin siRNA STAT1 . This STAT1-dependent constitutive expression K6a , independent JAK ( Janus family kinase ) . Thus simvastatin capable down-regulating constitutive interferon-inducible expression PC-related keratins K6a K17 . Therefore , class molecule potential treatment PC relate inherited disorder causative mutation resides inducible/repressible keratin gene K6a K17 . Simvastatin statins approve human use might deliver either orally , currently case cholesterol-lowering treatment , high therapeutic dos require skin reduction hyperkeratosis PC relate keratinize disorder , might achieve topical formulation .</brief_summary>
	<brief_title>Simvastatin Treatment Pachyonychia Congenita</brief_title>
	<detailed_description />
	<mesh_term>Nails , Malformed</mesh_term>
	<mesh_term>Pachyonychia Congenita</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Patients pachyonychia congenita know mutation keratin 6a . The use concomitant medication know interact simvastatin . This would include itraconazole , ketoconazole , fluconazole , gemfibrozil , verapamil , diltiazem , mibefradil , erythromycin , clarithromycin , telithromycin , cyclosporine , ritonavir , nefazodone , danazol , amiodarone , Rifampin , carbamazepine . During study subject must agree avoid grapefruit juice . Also exclude patient past history myopathy , impair liver function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>